TTFCA

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• ADHD [Insufficient Evidence]
• aging skin [Insufficient Evidence]
• Alzheimer dz [Insufficient Evidence]
• anal fissure [Insufficient Evidence]
• atherosclerosis [Insufficient Evidence]
• atopic dermatitis (eczema) [Insufficient Evidence]
• burns [Possibly Effective]
• chronic venous insufficiency [Possibly Effective]
• cognitive function [Possibly Ineffective]
• depression [Insufficient Evidence]
• diabetic foot ulcers [Insufficient Evidence]
• diabetic microangiopathy [Insufficient Evidence]
• dry skin [Insufficient Evidence]
• epilepsy [Insufficient Evidence]
• generalized anxiety disorder [Insufficient Evidence]
• hemorrhoids [Insufficient Evidence]
• herpes zoster (shingles) [Insufficient Evidence]
• HTN [Insufficient Evidence]
• hypertrophic scars [Insufficient Evidence]
• idiopathic interstitial pneumonia [Insufficient Evidence]
• keloids [Insufficient Evidence]
• laser skin resurfacing [Insufficient Evidence]
• osteoarthritis [Insufficient Evidence]
• radiation dermatitis [Possibly Ineffective]
• scarring [Insufficient Evidence]
• skin grafts [Insufficient Evidence]
• striae gravidarum (stretch marks) [Insufficient Evidence]
• SLE [Insufficient Evidence]
• tonsillitis [Insufficient Evidence]
• venous thromboembolism prophylaxis [Insufficient Evidence]
• wound healing [Insufficient Evidence]
• wrinkled skin [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

aging skin

[Insufficient Evidence]

Dose: apply 3% emulsion extract topically bid

atherosclerosis

[Insufficient Evidence]

Dose: 60 mg PO tid; Alt: 112.5 mg PO bid; 100 mg PO qd

burns

[Possibly Effective]

Dose: apply 3% cream topically qd; Alt: apply 5% dressing topically q3 days

chronic venous insufficiency

[Possibly Effective]

Dose: 60-180 mg PO qd

diabetic foot ulcers

[Insufficient Evidence]

Dose: apply 1.25% cream topically bid

diabetic microangiopathy

[Insufficient Evidence]

Dose: 60 mg PO bid

dry skin

[Insufficient Evidence]

Dose: apply 2% cream topically bid; Alt: apply 0.25 g (1% ointment) topically bid plus 1100 mg PO bid

generalized anxiety disorder

[Insufficient Evidence]

Dose: 500 mg PO bid

HTN

[Insufficient Evidence]

Dose: 4 g/250 mL tea PO tid

hypertrophic scars

[Insufficient Evidence]

Dose: apply 15% gel topically qd; Start: 2wk after surgery

idiopathic interstitial pneumonia

[Insufficient Evidence]

Dose: 225 mg PO tid

keloids

[Insufficient Evidence]

Dose: 450 mg PO qd; Start: 2wk after surgery

laser skin resurfacing

[Insufficient Evidence]

Dose: apply 0.05% gel topically qid x7 days, then apply bid

osteoarthritis

[Insufficient Evidence]

Dose: apply 25% cream topically qid

scarring

[Insufficient Evidence]

Dose: apply 1% cream topically tid; apply 2% cream topically bid

striae gravidarum (stretch marks)

[Insufficient Evidence]

Dose: 225 mg PO tid; Alt: apply cream or ointment topically qd-bid

wrinkled skin

[Insufficient Evidence]

Dose: apply 0.1-0.2% cream or gel topically qd-tid